loading

Innovative Applied Research through:

  • Establishing a unique, flagship Biobank with clinical, molecular, immunological data, and biological material from community-acquired severe pneumonia (sCAP) patients and mycotic infections,
  • Discovering innovative "immunoparalysis" biomarkers, a necessary prerequisite for future development of personalized immunotherapies,
  • Studying disturbances in the lung microenvironment, with an emphasis on characterizing the normal lung microbiome and dysbiosis following sCAP,
  • Integrating omics measurements with clinical, demographic, and epidemiological data to draw conclusions regarding the pathogenesis of infection and identify predictive markers of sCAP complications using machine learning algorithms.
To Top
en_US
el en_US
Skip to content